Updated May 2026
Sources & citations
Every clinical claim on OralGLPGuide.com is traceable to a primary source — FDA labels, peer-reviewed trials, official CMS rules — or a reputable secondary source corroborating one. This page aggregates every cited reference across the medication guides for transparent verification.
Primary
20
FDA labels, trial publications, CMS rules
Secondary
2
Reputable journalism, industry analysis
Tertiary
0
Encyclopedic / aggregator sources
Primary sources
Authoritative — FDA, peer-reviewed trials, official agency rules.
- 1. Medicare GLP-1 BridgeCenters for Medicare & Medicaid Services · accessed May 6, 2026Cited in: foundayo
- 2. Lilly's oral GLP-1 orforglipron demonstrated meaningful weight loss in ATTAIN-1Eli Lilly · accessed May 6, 2026Cited in: foundayo
- 3. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsEli Lilly Investor Relations · Apr 1, 2026 · accessed May 6, 2026Cited in: foundayo
- 4. Lilly launches additional Zepbound vial doses and offers new self-pay savingsEli Lilly Investor Relations · accessed May 7, 2026Cited in: zepbound
- 5. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets — Prescribing InformationNational Library of Medicine (DailyMed) · Nov 1, 2025 · accessed May 7, 2026Cited in: contrave
- 6. FOUNDAYO (orforglipron) tablets — Prescribing InformationNational Library of Medicine (DailyMed) · Apr 1, 2026 · accessed May 7, 2026Cited in: foundayo
- 7. MOUNJARO (tirzepatide) injection — Prescribing InformationNational Library of Medicine (DailyMed) · Apr 22, 2026 · accessed May 7, 2026Cited in: mounjaro
- 8. OZEMPIC (semaglutide) injection — Prescribing InformationNational Library of Medicine (DailyMed) · Oct 14, 2025 · accessed May 7, 2026Cited in: ozempic
- 9. QSYMIA (phentermine and topiramate extended-release) capsules — Prescribing InformationNational Library of Medicine (DailyMed) · Apr 22, 2026 · accessed May 7, 2026Cited in: qsymia
- 10. RYBELSUS (oral semaglutide) tablet — Prescribing InformationNational Library of Medicine (DailyMed) · Jan 1, 2026 · accessed May 7, 2026Cited in: rybelsus
- 11. SAXENDA (liraglutide) injection — Prescribing InformationNational Library of Medicine (DailyMed) · Feb 1, 2026 · accessed May 7, 2026Cited in: saxenda
- 12. ZEPBOUND (tirzepatide) injection — Prescribing InformationNational Library of Medicine (DailyMed) · Apr 1, 2026 · accessed May 7, 2026Cited in: zepbound
- 13. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)NEJM · accessed May 7, 2026Cited in: mounjaro
- 14. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)NEJM · accessed May 7, 2026Cited in: ozempic
- 15. Oral Semaglutide versus Placebo in Type 2 Diabetes (PIONEER-1)NEJM · accessed May 7, 2026Cited in: rybelsus
- 16. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)NEJM · accessed May 7, 2026Cited in: saxenda
- 17. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)NEJM · accessed May 7, 2026Cited in: zepbound
- 18. Wegovy pill (oral semaglutide 25 mg) approved for weight management — OASIS-4 phase III dataNovo Nordisk · Dec 22, 2025 · accessed May 7, 2026Cited in: wegovy-tablets
- 19. Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025Novo Nordisk / PR Newswire · Nov 4, 2025 · accessed May 7, 2026Cited in: wegovy-tablets
- 20. ATTAIN-2 — orforglipron in adults with T2D and obesityThe Lancet · accessed May 6, 2026Cited in: foundayo
Secondary sources
Reputable journalism + industry analysis. Used for corroboration; never for clinical claims standing alone.
- 1. FDA approves first GLP-1 pill for obesity from Novo NordiskCNBC · Dec 22, 2025 · accessed May 7, 2026Cited in: wegovy-tablets
- 2. Eli Lilly's obesity pill approved by FDASTAT News · Apr 1, 2026 · accessed May 6, 2026Cited in: foundayo
Sourcing rules
- Every clinical claim must be traceable to a primary source.
- News reporting (STAT, Reuters, NYT, CNBC) is acceptable as secondary corroboration but cannot stand alone for clinical claims.
- Manufacturer press releases are primary for pricing and approval-date facts, secondary for clinical claims.
- Citations are timestamped with the date accessed; if a source moves or changes, the version we cited is what we relied on at publication.
Read the full editorial standards for the 12-point rubric and conflict-of-interest policy.